Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease  by Schieffer, Bernhard et al.
C
a
o
A
B
R
H
I
o
e
(
(
e
I
T
t
s
a
g
f
H
a
D
F
S
2
Journal of the American College of Cardiology Vol. 44, No. 2, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2004.03.065Anti-Inflammatory Therapy in Coronary Artery Disease
omparative Effects of AT1-Antagonism
nd Angiotensin-Converting Enzyme Inhibition
n Markers of Inflammation and Platelet
ggregation in Patients With Coronary Artery Disease
ernhard Schieffer, MD,* Christoph Bu¨nte, MS,* Jana Witte, MS,* Kirsten Hoeper, RN,*
ainer H. Bo¨ger, MD,† Edzard Schwedhelm, PHD,† Helmut Drexler, MD*
annover and Hamburg-Eppendorf, Germany
OBJECTIVES We evaluated whether renin-angiotensin system (RAS) blockade attenuates cardiovascular
events.
BACKGROUND Because inflammation and enhanced thrombogenesis are hallmarks of atherosclerosis, we
assessed whether RAS inhibition elicits anti-inflammatory and anti-aggregatory effects.
METHODS Interleukin 6 (IL-6), high-sensitivity C-reactive protein (hsCRP), metalloprotease 9 (MMP-
9), and interleukin 10 (IL-10) were determined in patients with coronary artery disease
(CAD) and arterial hypertension six to eight weeks after coronary angioplasty (low-density
lipoprotein serum levels 150 mg/dl). Patients were randomized double-blind to either 20
mg enalapril (ENAL, n  27) or 300 mg irbesartan (IRB, n  21) for 3 months. Blood
samples were drawn at baseline and at three months. Thromboxane A2-induced platelet
aggregation was determined turbidimetrically; urine bicyclo-prostaglandin E2 (PGE2) and
inflammatory markers were measured by enzyme-linked immunosorbent assay technique.
RESULTS Both treatment regimens enhanced serum IL-10 levels (IRB p  0.001, ENAL p  0.03)
and reduced serum MMP-9 protein (IRB p  0.001, ENAL p  0.05) and MMP-9 activity
(IRB p  0.005, ENAL p  0.05). Only IRB reduced serum IL-6 and hsCRP levels
significantly compared with baseline (p  0.01), whereas ENAL did not (hsCRP p  0.02
IRB vs. ENAL, p  0.01 IRB vs. ENAL). Platelet aggregation was only reduced by IRB (p
 0.001, ENAL p  0.06, IRB vs. ENAL p  0.001) while urine PGE2 levels remained
unchanged.
CONCLUSIONS Angiotensin-converting enzyme (ACE) inhibition and angiotensin II type 1 receptor (AT1)
blockade reduced serum MMP-9 protein/activity to a similar extent, and only AT1 blockade
reduced hsCRP, IL-6, and platelet aggregation in patients with CAD. Thus, AT1-blockade
appears to exert stronger systemic anti-inflammatory and anti-aggregatory effects compared
with ACE inhibition. (J Am Coll Cardiol 2004;44:362–8) © 2004 by the American
College of Cardiology Foundationi
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pnflammation and enhanced thrombogenesis are hallmarks
f atherosclerosis (1) and markers of inflammation; for
xample, interleukin 6 (IL-6) and C-reactive protein (CRP)
2) are elevated in patients with coronary artery disease
CAD). In contrast, cytokines such as interleukin (IL)-10
licit anti-atherosclerotic effects in vitro and in vivo (3–6).
nterleukin-10 has deactivating effects on macrophages,
-cells, and cyclooxygenase-2 (COX-2) and metallopro-
eases (MMPs) (7–10). Interleukin-10 further decreases
erum cholesterol levels (11) and may thereby contribute to
therosclerotic plaque’s stabilization by increasing its colla-
en content and decreasing MMP activity (9–12). There-
ore, the balance of pro- (IL-6, CRP) and anti-
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ynthelabo.
Manuscript received November 7, 2003; revised manuscript received February 25,t004, accepted March 16, 2004.nflammatory (IL-10) mediators may be important for both
he stability of atherosclerotic lesions and the perpetuation
f atherosclerotic plaques (3,12,13).
Long-term blockade of the renin-angiotensin system
RAS), as shown in the Heart Outcome and Prevention
valuation (HOPE) or in the EUROPA study (EURopean
rial On reduction of cardiac events with Perindopril in
table coronary Artery disease), significantly reduced cardio-
ascular events such as unstable angina, myocardial infarc-
ion, or stroke in patients with established atherosclerosis
14,15). In this regard, recent observations from our labo-
atory raised the possibility that the beneficial effects of
ngiotensin-converting enzyme (ACE) inhibitors may be in
art related to an interaction of RAS components with
nflammatory cytokines, such as IL-6 (16). Importantly,
L-6 serum levels were shown to be elevated in patients with
nstable angina (17) and have been implicated in the
rognosis of patients with acute coronary events (2).
Furthermore, the HOPE investigators reported that pa-ients with elevated urine 11-dehydro-thromboxane B2
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July 21, 2004:362–8 Anti-Inflammatory Effects of AT1-AntagonistsTXB2) had a higher risk of acute coronary events (18).
ecause prostaglandins (PGs) may be generated by COX
19,20) and thereby combine inflammation with thrombosis
1), it was suggested that TXA2 (and its urine derivate
1-dehydro-TXB2) may also contribute to the development
f acute coronary syndromes in patients with established
AD.
Besides ACE inhibitors, angiotensin II type 1 (AT1)
eceptor antagonists elicit beneficial effects in various experi-
ental models of atherosclerosis in primates (21) by suppress-
ng plaque formation and surrogate markers of atherogenesis.
oreover, results from our laboratory demonstrated that AT1-
lockade by losartan may reduce platelet aggregation in vitro
nd in vivo via its metabolite EXP3179 (22). Therefore,
otential systemic anti-inflammatory, anti-aggregatory, and
nti-collagenolytic effects of long-term ACE inhibition with
T1-recceptor blockade were compared in a double-blind
andomized study in patients with CAD. Interleukin-10 serum
evels were determined as potential anti-atherosclerotic surro-
ate markers. In order to evaluate the involvement of COX-
ependent pathways, urine bicyclo prostaglandin E2 (PGE2)
as determined.
ATERIALS AND METHODS
tudy subjects. Sixty patients with established CAD and
rterial hypertension were enrolled. Patients were screened
hile scheduled for elective percutaneous transluminal cor-
nary angioplasty in our department and enrolled six to
ight weeks after coronary angioplasty. All patients had
ngiographically documented CAD without flow-limiting
oronary stenosis (50%). Patients agreed to participate in
his double-blind randomized study and were assigned to
nalapril or irbesartan according to a randomization list.
edication was blinded by the Department of Pharmacol-
gy. None of the patients reported symptoms of angina or
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ANG II  angiotensin II
AT1  angiotensin II type 1 receptor
BP  blood pressure
CAD  coronary artery disease
COX  cyclooxygenase
ENAL  enalapril
EUROPA  European Trial on Reduction of Cardiac
Events With Perindopril in Stable
Coronary Artery Disease
hsCRP  high-sensitivity C-reactive protein
HOPE  Heart Outcome and Prevention Evaluation
IL  interleukin
IRB  irbesartan
MMP  metalloprotease
PG  prostaglandin
RAS  renin-angiotensin system
TXA2  thromboxane A2eart failure at the time of inclusion into the study. Patients aeceived echocardiography and exercise stress tests before
andomization as required safety parameters by the local
thical committee. Patients receiving ACE-inhibitors,
T1-receptor blockers, HMG-CoA reductase inhibition,
r nonsteroidal anti-inflammatory drugs (NSAID) were
xcluded, with the exception of 100 mg of aspirin. Patients
ith chronic renal failure, low-density lipoprotein serum
evels 150 mg/dl, or hypotension (systolic blood pressure
BP] 90 mm Hg) were excluded. Patients were random-
zed to either 2  10 mg enalapril (group A, ENAL) or 2
150 mg irbesartan (group B, IRB) per day; the dosage
as established based on their BP-lowering potencies. One
atient in the enalapril group did not complete the study
ecause of symptomatic hypotension. Eleven patients were
xcluded from the analysis because of study protocol viola-
ions. Of those, eight patients started with NSAID and
hree patients started with HMG CoA reductase inhibitors
uring the study. Four patients in the irbesartan group and
ix patients in the enalapril group had diabetes (Table 1);
f those, one patient in each group received oral medication.
lood sampling and laboratory analysis. At baseline and
fter three months serum and urine samples were collected.
lood samples were drawn in seated position from the
ntecubital vein and serum/urine samples were stored at
80°C before use. Interleukin-6 (pg/ml), hsCRP, MMP-9
ng/ml), and MMP-9 activity (ng/ml) were used as markers
f inflammation, IL-10 (pg/ml) as a potential antagonist:
L-6, IL-10, and total MMP-9 were measured using an
nzyme-linked immunabsorbent assay technique (Quan-
ikine, R and D Systems, Minneapolis, Minnesota). Intra-
ssay reproducibility from triplicate analysis was below 5%
n all samples.
etalloprotease activity. Metalloprotease-9 activity was
nalyzed using a fluorometric assay (Fluorokine, R and D
ystems) designed to quantitatively measure enzyme ac-
ivity. Therefore, a monoclonal antibody specific for
MP-9 was coated onto a microplate, standards and
amples were added into the wells, and any MMP-9 was
ound by the immobilized antibody. After any unbound
ubstances were washed away, an activation reagent (p-
able 1. Characteristics of Study Subjects
Irbesartan Enalapril
ubjects 21 27
ale/female 16/5 20/7
ge 56  8 58  13
ody mass index (kg/m2) 27.5  4 28.5  6
iabetics 4 6
aseline blood pressure (mm Hg)
Systolic 147  35 143  23
Diastolic 88  16 84  16
-month blood pressure (mm Hg)
Systolic 133  19† 133  22†
Diastolic 83  9* 80  12*
p 0.05 vs. baseline diastolic pressure, †p 0.01 vs. baseline systolic blood pressure.
ystolic and diastolic blood pressure was not significant between groups.minophenylmercuric acetate) was added to all samples.
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Anti-Inflammatory Effects of AT1-Antagonists July 21, 2004:362–8fter a wash, a fluorogenic substrate linked to a quencher
olecule was added and any active enzyme present would
leave the peptide linker between the fluorophore and the
uencher molecule. This cleavage eliminates the distance-
ependent resonance energy transfer between the fluoro-
hore and the quencher molecule, allowing a fluorescent
ignal that is proportional to the amount of enzyme activity
n the sample. The kit is designed to measure the levels of
oth endogenous active MMP-9 in the samples and the
MP-9 in those samples that can be activated by APMA
uring the assay procedure. Each sample was measured in
riplicets; data are given as mean  SEM.
latelet aggregation. Whole blood was collected in 10%
cid-citrate-dextrose at baseline and at 3 months, and
latelet-rich plasma was generated as previously described
22). Platelets were stimulated with U46619 (107 M), a
XA2 analog. Aggregation was determined turbimetrically
aggregometer APACT Inc., Achensburg, Germany).
hrombin (10 U/ml) was used as TXA2-independent
timulus of platelet aggregation. Each experiment was
erformed in duplicate; results were given as mean  SEM.
icyclo PGE2 analysis. Bicyclo PGE2 was assayed by a
ommercially available enzyme-linked immunosorbent assay
it (Cayman Chemicals, Ann Arbor, Michigan) (23,24).
ata were analyzed in triplicets and are given as mean 
EM.
igh-sensitivity CRP. Plasma samples obtained at base-
ine and after three months were thawed and assayed for
RP using a high-sensitivity assay with a coefficient of
ariation below 5% (Dade Behring using a BN II nephe-
ometer analyzer, FDA-approved). The limits of detection
0.02 mg/l) and quantification (0.15 mg/l) were reported
ecently (25).
tatistical analysis. Sample size was calculated for an
ndependent t test for comparison of means assuming 50%
ifference in platelet aggregation, two-tailed of 0.05 for
latelet aggregation and for analysis of variance for the
emaining parameters. Sixty patients were required to obtain
power of 80% to detect a 30% difference in platelet
ggregation as primary end point. The t test was performed
wo-sided; p values 0.05 were considered statistically
ignificant.
ESULTS
linical parameters of study subjects are summarized in
ables 1 and 2. Groups did not differ with regard to body
ass index, gender, cardiovascular risk factors, or medica-
ion. None of the patients reported symptoms of angina or
eart failure at the time of inclusion into the study, and
herefore the treatment regimens could not test the impact
n clinical symptoms. At baseline and after three months of
herapy, no differences with regard to serum electrolytes,
enal function, or blood cell counts were recorded between
he groups. Systolic BP was significantly lower at three
onths compared with baseline conditions; treatment ef- aects were not different between the groups (Tables 1 and 2).
iastolic BP was significantly reduced to a similar extent in
oth groups. There were no significant changes in left
entricular function and exercise stress test for both groups
efore and after three months of therapy. In both groups,
erum levels of IL-10 were significantly elevated after three
onths of therapy as compared with baseline levels (Fig. 1)
IRB vs. ENAL n.s.). In contrast, both treatment regimens
esulted in significantly reduced circulating levels of
MP-9 (IRB vs. ENAL n.s.) and MMP-9 activity (Fig. 2)
IRB vs. ENAL n.s.). However, only IRB reduced IL-6 and
sCRP levels significantly compared with baseline (p 
.01) and to ENAL (hsCRP: IRB vs. ENAL p  0.02;
L-6: IRB vs. ENAL p 0.01) (Fig. 3). Angiotensin I type
-receptor blockade reduces thromboxane A2 (TXA2)-
nduced platelet aggregation in vitro and in vivo (22). To
ddress whether this latter involves a cyclo-oxygenase de-
endent mechanism, TXA2-induced platelet aggregation as
ell as urine bicyclo (PGE2 was determined. Figure 4 shows
hat only IRB reduced TXA2-induced platelet aggregation
ignificantly compared with baseline (p  0.001). More-
ver, the IRB effect on platelet aggregation was significantly
ifferent compared to ENAL (p  0.001). Urine bicyclo
GE2 was determined because circulating PGE2 is rapidly
egraded to 13,14-dihydro-15-keto PGE2 (PGE2-M, t1/2
3 min), being converted to prostaglandin A products
able 2. Baseline Laboratory Parameters of All Study Subjects
Irbesartan Enalpril
otal cholesterol (mg/dl) 201  15 187  22
DL (mg/dl) 115  17 124  22
reatinine (mol/l) 89  27 83  22
 (mmol/l) 4.4  0.4 4.6  0.3
a (mmol/l) 142  3 142  4
b (g/dl) 14.6  1.5 14.6  1.8
eucocytes (103/l) 6.4  2.6 7.4  1.9
.s. for all parameters depicted.
LDL  low density lipoprotein.
igure 1. Impact of renin-angiotensin system inhibition on interleukin-10
IL-10). Patients were treated for 3 months with either 20 mg enalapril
ENAL, white bars) or 300 mg of irbesartan (IRB, black bars); IL-10
erum concentrations were determined by enzyme-linked immunosorbent
ssay technique at baseline and at 3 months. Data represent mean SEM.
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July 21, 2004:362–8 Anti-Inflammatory Effects of AT1-Antagonistsn considerable extent (25,26). Urinary PGE2 excretion
emained unchanged between the groups and as compared
o baseline conditions suggesting a cyclo-oxygenase-
ndependent mechanism (Fig. 5).
ISCUSSION
he present study shows that RAS blockade, ACE inhibi-
ion, and AT1-receptor blockade enhance serum levels of
L-10 and reduce MMP-9 protein/activity in patients with
ngiographically documented CAD. However, circulating
evels of IL-6, hsCRP and TXA2-induced platelet aggre-
ation were only reduced by AT1 receptor blockade. These
ndings suggest that the continual activation of an acute-
hase reaction in patients with CAD (as determined by
igure 2. Renin-angiotensin system inhibition and metalloprotease 9
MMP9). Concentration of serum MMP9 protein was determined by
nzyme-linked immunosorbent assay and its serum activity was fluoro-
etrically analyzed by enzyme immunosorbent assay zymography. Patients
ere treated for 3 months with either 20 mg enalapril (white bars) or 300
g of irbesartan (black bars) and blood samples were drawn at baseline and
t 3 months. Bar graphs summarize individual -changes in serum MMP9
nd MMP9 activity over a three-month observation period. Data are given
s mean  SEM.
igure 3. Impact of renin-angiotensin system inhibition on surrogate
arkers of inflammation. Bar graphs summarize individual -changes in
erum high-sensitivity C-reactive protein (hsCRP) and interleukin-6 levels
ver a three-month observation period in patients with coronary artery
isease and hypertension. Patients were treated with either 20 mg of
nalapril (white bars) or 300 mg Irbesartan (black bars) and interleukin-6
erum levels were determined by enzyme-linked immunosorbent assay.
ata are given as mean  SEM. blevated hsCRP and IL-6 levels) may be suppressed more
ffectively by long-term AT1 blockade than by ACE inhi-
ition.
Serum markers of inflammation such as hsCRP and IL-6
re elevated in patients with unstable angina (2,17) and are
redictors of recurrent cardiovascular events (2,17,27). In
cute and chronic inflammatory processes, IL-6 promotes
-cell differentiation, acute-phase protein synthesis, smooth
uscle cell proliferation (28), and the release of metallo-
roteases involved in extracellular matrix degradation.
nterleukin-6 regulates the expression of adhesion molecules
nd other cytokines such as IL-1 beta and tumor necrosis
igure 4. Renin-angiotensin system inhibition and platelet aggregation.
latelet-rich plasma from patients treated with either 20 mg enalapril
white bars) or 300 mg irbesartan (black bars) was isolated (all received
00 mg acetyl salicylic acid). Platelet aggregation was determined turbi-
etrically after U46619 stimulation (a synthetic thromboxane A2-analog).
ar graph summarizes individual -changes of platelet aggregation in
atients with coronary artery disease and hypertension. Data represent
ean  SEM.
igure 5. Renin-angiotensin system inhibition and urine bicyclo-
rostaglandin E2 (PGE2). High-sensitivity C-reactive protein was deter-
ined in urine samples from patients treated with either 20 mg enalapril or
00 mg irbesartan and normalized to serum creatinine levels. All patients
eceived 100 mg acetyl salicylic acid. Prostaglandin E2 was determined by
nzyme-linked immunosorbent assay. Both treatment regimens had no
ignificant impact on urine bicyclo-PGE2, which is predominantly secreted
y platelets, indicating a cyclo-oxygenase-independent mechanism. White
ars  enalapril; black bars  irbesartan.
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Anti-Inflammatory Effects of AT1-Antagonists July 21, 2004:362–8actor alpha (28). These effects may amplify the inflamma-
ory reaction at the atherosclerotic lesion and subsequently
ontribute to the plaques’ fibrous cap decomposition
13,29).
Although most of these observations were obtained in
itro, it is possible that circulating serum IL-6 may activate
irculating inflammatory cells (e.g., monocytes) to enter the
essel wall, inducing cell differentiation and the presentation
f adhesion molecules at the luminal site of the vessel wall.
oreover, circulating IL-6 may easily diffuse into the vessel
all and act locally by inducing monocyte recruitment,
ctivating MMPs, and enhancing the expression of adhe-
ion molecules (28). Thus, reducing circulating levels of
L-6 with long-term AT1-receptor blockade, as reported in
he present study, may be a pathophysiologic mechanism
nvolved in atherosclerotic plaque progression and instability
nd may therefore be of therapeutic interest.
In addition, an activated RAS is associated with a higher
ncidence of acute coronary syndromes (30). Moreover,
CE is expressed at the shoulder region of atherosclerotic
esions (31) and ACE activity is enhanced in coronary
amples of patients with unstable angina (32). Both IL-6
nd angiotensin II (ANG II) are co-localized in stable and
nstable plaques (16), and ANG II enhances synthesis and
elease of IL-6 (16,33). In this regard, our present study
hows that AT1-receptor blockade reduces plasma levels of
L-6 in patients with CAD. Whether or not this effect
eflects the local pathophysiology at the atherosclerotic
esions or represents a more systemic effect needs further
nvestigation.
Although ACE inhibition does not reduce IL-6 and
RP, the effect of ACE inhibition and AT1-blockade on
MP-9 protein and activity was comparable. Thus, while
he effects of AT1-blockade may be related to blockade of
NG II and its receptor, the ACE-inhibitor effect may be
elated to bradykinin, because long-term ACE inhibition
nhances circulating bradykinin levels and consequently
nhances the release of nitric oxide. There is experimental
vidence that nitric oxide abolishes MMP-9 activity and
ncreases tissue inhibitors of metalloproteases (34). Thus,
nalapril and irbesartan may reduce MMP-9 activity (de-
pite dissimilar effects on hsCRP or IL-6) by different
echanisms. In the case of AT1-blockade, the more com-
lete blockade of ANG II-AT1-receptor-mediated effects
ay be the predominant mechanism, whereas ACE inhi-
ition may elicit this effect via bradykinin and nitric oxide.
hether or not the effect of AT1-blockade also involves the
timulation of the ANG II type 2 receptor remains to be
etermined.
In addition, long-term AT1-receptor blockade dimin-
shes TXA2-induced platelet aggregation in the present
tudy. In patients with CAD, TXA2 may play a critical role
ased on its vasoconstrictor and mitogenic potencies (35). A
ajor urinary metabolite of TXA2 is elevated in patients
ith unstable angina (35,36), and the major portion of this
etabolite is believed to come from activated platelets. eikelboom et al. (18) reported that those patients enrolled
n the HOPE trial whose urinary 11-dehydro TXB2 levels
ere in the highest quartile had a higher risk of cardiovas-
ular events compared with those subjects in the lowest
uartile. Similarly, we report that AT1-receptor blockade
educes TXA2-induced platelet aggregation but may be
yclo-oxygenase independent because urinary PGE2 con-
entrations were unaffected. Although the underlying
echanism needs further investigation, this effect may
ossibly be mediated either by a direct inhibition of irbe-
artan at the TXA2-receptor (22) or by active metabolites of
rbesartan (37). Similarly, beneficial effects of ACE inhibi-
ors on platelet aggregation have been determined ex vivo by
hole-blood aggregometry (not in platelet-rich plasma with
pecific stimuli, as shown in the present study), but the
nderlying mechanisms remained unclear (38). Moreover,
e have demonstrated that AT1-receptor blockade specif-
cally reduced TXA2-dependent effects in platelets, an effect
hat has not been reported for ACE inhibitors and that may
e beyond the blockade at the AT1-receptor. Nevertheless,
he present observations were made in a relatively small
opulation of patients and therefore confirmation in large
atient populations is warranted.
Mean values for hsCRP levels were slightly elevated in
oth groups, an observation that has been reported previ-
usly (39). Moreover, the main focus of our study was to
ompare long-term ACE inhibition with long-term AT1-
eceptor blockade on markers of inflammation because
revious observations in patients with mild to moderate
AD reported not only that pro-inflammatory markers
uch as VCAM-1 or tumor necrosis factor alpha are
ncreased, but also that irbesartan may reduce these markers
f inflammation significantly (40,41). Despite a very similar
eduction of BP (Table 1), the decrease of hsCRP and IL-6
as significantly different between the treatment groups.
Moreover, one could speculate that the suppressive effect
f AT1-receptor blockade and ACE inhibition may be dose
elated and may be dependent on the tissue affinity of the
CE inhibitor used (i.e., enalapril vs. ramipril or perindo-
ril). These effects, however, do not involve systemic BP
ffects, because both drugs (300 mg of irbesartan and 20 mg
f enalapril) elicited similar BP-lowering effects in our
tudy. Nevertheless, 300 mg irbesartan may produce addi-
ional tissue effects that are ANG II-AT1-receptor depen-
ent and AT1-receptor independent. In this regard, it is of
articular interest that atheroclerostic lesions contain ANG
I-forming enzymes (with ACE activity), such as chymase
nd cathepsin G (42), which represent an alternative path-
ay of ANG II-formation unaffected by ACE inhibitors
ith various tissue affinity. Therefore, we suggested that
nhibitors of the AT1-receptor may elicit a more complete
lockade of ANG II-proinflammatory and procoagulatory
ffects at the AT1-receptor level as compared to ACE
nhibitors by blocking ANG II-AT1 receptor-dependent
ffects and by developing anti-inflammatory pleiotropic
ffects via anti-inflammatory metabolites.
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July 21, 2004:362–8 Anti-Inflammatory Effects of AT1-AntagonistsFinally, it should be noted that it is unclear whether
erum composition of pro- or anti-inflammatory markers
nd MMPs reflect the local vascular inflammatory state at
he atherosclerotic lesion. Circulating cytokines such as
L-10 or IL-6, however, may well diffuse easily into the
therosclerotic wall and thereby modulate activation and/
r differentiation of circulating or adherent inflammatory
ells (e.g., monocytes to active macrophages) or cause
-lymphocytes to enter the atherosclerotic wall. Thus,
levated serum levels of both pro- or anti-inflammatory
ytokines may have the potential to modulate local inflam-
atory processes that subsequently would contribute to
laque destabilization or passivation.
Nevertheless, although convincing experimental and
mall-scale clinical studies with AT1-antagonists exist,
arge-scale clinical trials with AT1-antagonists in patients
ith CAD are still missing and we cannot exclude a late and
ndividual decline in some of the parameters in our patients.
herefore, actual clinical recommendation for patients with
AD should primarily focus on ACE inhibitors for RAS
nhibition, based on the results from the HOPE and
UROPA trials.
eprint requests and correspondence: Dr. Bernhard Schieffer,
epartment of Cardiology and Angiology, Carl-Neuberg-Str. 1,
0625 Hannover, Germany. E-mail: Schieffer.Bernhard@MH-
annover.de.
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